内镜下经腔入路与微创手术相比可减少坏死性胰腺炎患者的并发症和费用
一项单中心随机试验纳入66例确诊或疑似感染性坏死性胰腺炎需干预的患者,比较内镜下经腔升阶梯治疗与微创手术。内镜组主要并发症或死亡复合终点发生率为11.8%,手术组为40.6%(风险比0.29,95%CI 0.11-0.80,P=0.007),内镜组费用更低且3个月生活质量生理健康评分更好。
要点
- 内镜经腔入路较微创手术显著降低主要并发症或死亡复合终点(11.8% vs 40.6%,RR 0.29)。
- 内镜组无患者发生肠瘘或胰皮瘘,手术组为28.1%(P=0.001)。
- 两组死亡率无显著差异(内镜8.8% vs 手术6.3%,P=0.999)。
核心结论
- 在66例感染性坏死性胰腺炎的随机试验中,与微创手术相比,内镜下经腔入路显著减少主要并发症、降低费用并提高生活质量。
研究设计与样本
- 单中心随机试验,纳入66例确诊或疑似感染性坏死性胰腺炎需干预的患者,随机分为微创手术组(n=32)和内镜下升阶梯治疗组(n=34)。
- 干预时间范围为2014年5月12日至2017年3月24日。
主要发现
- 主要终点(6个月随访期间主要并发症复合终点或死亡)发生率内镜组11.8% vs 手术组40.6%(风险比0.29;95%CI 0.11-0.80;P=0.007)。
- 死亡率内镜组8.8% vs 手术组6.3%(P=0.999),无显著差异。
- 肠瘘或胰皮瘘发生率内镜组0% vs 手术组28.1%(P=0.001)。
- 每例患者平均主要并发症数手术组0.69±1.03 vs 内镜组0.15±0.44(P=0.007)。
- 3个月生活质量生理健康评分内镜组更优(P=0.039),平均总费用内镜组75,830美元 vs 手术组117,492美元(P=0.039)。
关键数值与推荐
- 主要终点为6个月随访期间主要并发症(新发多器官衰竭、新发系统性功能障碍、肠瘘或胰皮瘘、出血及内脏器官穿孔)复合终点或死亡。
- 微创手术组根据积液位置选择腹腔镜或视频辅助腹膜后清创。
- 内镜组采用经腔引流伴或不伴坏死组织清除的升阶梯治疗。
临床怎么用
- 对于感染性坏死性胰腺炎需干预的患者,内镜下经腔升阶梯治疗与微创手术相比可减少主要并发症、降低费用并提高生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Infected necrotizing pancreatitis is a highly morbid disease with poor outcomes. Intervention strategies have progressed from open necrosectomy to minimally invasive approaches. We compared outcomes of minimally invasive surgery vs endoscopic approaches for patients with infected necrotizing pancreatitis. METHODS: We performed a single-center, randomized trial of 66 patients with confirmed or suspected infected necrotizing pancreatitis who required intervention from May 12, 2014, through March 24, 2017. Patients were randomly assigned to groups that received minimally invasive surgery (laparoscopic or video-assisted retroperitoneal debridement, depending on location of collection, n = 32) or an endoscopic step-up approach (transluminal drainage with or without necrosectomy, n = 34). The primary endpoint was a composite of major complications (new-onset multiple organ failure, new-onset systemic dysfunction, enteral or pancreatic-cutaneous fistula, bleeding and perforation of a visceral organ) or death during 6 months of follow-up. RESULTS: The primary endpoint occurred in 11.8% of patients who received the endoscopic procedure and 40.6% of patients who received the minimally invasive surgery (risk ratio 0.29; 95% confidence interval 0.11-0.80; P = .007). Although there was no significant difference in mortality (endoscopy 8.8% vs surgery 6.3%; P = .999), none of the patients assigned to the endoscopic approach developed enteral or pancreatic-cutaneous fistulae compared with 28.1% of the patients who underwent surgery (P = .001). The mean number of major complications per patient was significantly higher in the surgery group (0.69 ± 1.03) compared with the endoscopy group (0.15 ± 0.44) (P = .007). The physical health scores for quality of life at 3 months was better with the endoscopic approach (P = .039) and mean total cost was lower ($75,830) compared with $117,492 for surgery (P = .039). CONCLUSIONS: In a randomized trial of 66 patients, an endoscopic transluminal approach for infected necrotizing pancreatitis, compared with minimally invasive surgery, significantly reduced major complications, lowered costs, and increased quality of life. Clinicaltrials.gov no: NCT02084537.
引用
- Bang JY, Arnoletti JP, Holt BA, et al. An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis. Gastroenterology. 2018. PMID: 30452918. doi:10.1053/j.gastro.2018.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。